Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Joe Biden warns China over threats to US sovereignty in State of the Union address
    • Fed chair warns of even higher rates if jobs data stays strong
    • Erdoğan declares state of emergency in Turkey after deadly earthquake
    • Iran’s ‘ghost fleet’ switches into Russian oil
    • Chinese spy balloon incursion reveals past US intelligence failings
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Ammunition supply chain crisis: Ukraine war tests Europe in race to rearm
      • Gautam Adani’s ports business to repay $600mn in race to cut debt
      • Jupiter dumps Starling Bank and rules out unlisted stocks
      • BP slows oil and gas retreat after record $28bn profit
      • Carlsberg seeks buyback clause as it nears exit from Russia
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from February 7: Ukraine’s allies to send up to 178 tanks, Sunak reshuffles cabinet
      • Iran’s ‘ghost fleet’ switches into Russian oil
      • Russia’s budget deficit soars as energy revenues slump by almost half
      • Live news: UK regulator deals blow to Microsoft’s $75bn Activision deal
      • Jupiter dumps Starling Bank and rules out unlisted stocks
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Lessons from the great reflation
      • Are CEOs with MBAs good for business?
      • Brexit could be reversed — here’s how
      • A Republican-led US would not shrink from the world
      • We should all be asking more questions
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Barclays chief: the life lessons I have discovered during cancer treatment
      • Management research: why are so few of its ideas taken up?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How to ski, shop, sled and sip it in St Moritz
      • American Resistance by David Rothkopf — managing the Trump horror show
      • Hogwarts Legacy review — 1890s-set prequel is a step forward for Harry Potter
      • Inside Vermelho, Christian Louboutin’s new hotel
      • How long would you wait for a steak?
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Hannah Kuchler

    Global Pharmaceuticals Correspondent

    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 29 January, 2023
      Drugs research
      RQ Bio partners with AstraZeneca in Covid antibody fight

      UK biotech racing to keep antibody up to date with latest variants

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Monday, 16 January, 2023
      Drug prices
      US drugmakers withdraw from NHS pricing agreement as costs soar

      AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales

    • Monday, 16 January, 2023
      Bayer AG
      Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe

      German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China

    • Friday, 13 January, 2023
      UK politics & policy
      UK government admits R&D-heavy small companies need more tax help

      Business groups cautiously welcome acknowledgment that reform ‘creates challenges for some SMEs’

    • Friday, 13 January, 2023
      UK social care
      Private care homes push for sharp rise in prices to take on NHS patients

      Operators say higher tariff would allow them to attract and keep staff as hospitals look to free up space

    • Tuesday, 10 January, 2023
      Elliott Management Corp
      Elliott portfolio manager behind GSK and Fresenius campaigns leaves firm

      Sebastien de La Riviere’s move is latest in a number of high-profile departures inside activist’s London office

    • Tuesday, 10 January, 2023
      BioNTech
      BioNTech buys UK AI start-up InstaDeep in £562mn deal

      Covid vaccine maker looks to use machine learning to help discover new treatments

    • Monday, 9 January, 2023
      National Health Service
      UK health leaders question impact of cash on freeing up hospital beds

      Call for ‘urgent clarification’ on ministers’ plans for up to £250mn going towards easing pressure on NHS

    • Monday, 9 January, 2023
      AstraZeneca PLC
      AstraZeneca to buy US biotech CinCor in $1.8bn deal

      Agreement is one of several announced as major healthcare conference begins in San Francisco

    • Friday, 6 January, 2023
      Covid-19 vaccines
      New Chinese mRNA Covid vaccine shows positive early results

      Jab developed by CanSinoBio could help nation grappling with a wave of infection

    • Friday, 6 January, 2023
      Coronavirus economic impact
      Ambulances left waiting for record times as ‘twindemic’ hits UK

      Covid and flu hospitalisations soar over Christmas as emergency service delays worsen

    • Friday, 6 January, 2023
      News in-depthDrugs research
      A pharma partnership that brought a breakthrough in breast cancer

      Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing

    • Friday, 6 January, 2023
      Medical science
      UK signs deal with BioNTech for cutting-edge cancer trials

      Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS

    • Wednesday, 4 January, 2023
      Pharmaceuticals sector
      Pharmacists in UK and US report shortage of cold and flu medicines

      Early winter surge in respiratory infections puts pressure on drugmakers to meet demand

    • Monday, 2 January, 2023
      The Big Read
      The start-ups seeking a cure for old age

      Tech billionaires are funding research to help us live longer and healthier lives, but experts warn of an ethical minefield ahead

    • Friday, 30 December, 2022
      GSK PLC
      GSK on hunt for attractive biotechs ‘hiding in plain sight’

      Chief commercial officer Luke Miels looking at targets worth up to $2.5bn

    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Wednesday, 21 December, 2022
      ExplainerAntibiotic resistance
      Surge in infections leads to global shortage of antibiotics

      Manufacturers struggle to keep pace with post-pandemic demand as dozens of countries report low supply of drugs

    • Tuesday, 20 December, 2022
      Galapagos NV
      Belgian biotech company Galapagos on the hunt for deals

      Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off

    • Thursday, 15 December, 2022
      Health
      UK issues ‘serious shortage’ protocol for penicillin

      Move enables pharmacists to prescribe alternative formulations of antibiotics after rise in cases of Strep A

    • Thursday, 15 December, 2022
      Drug prices
      Gene therapies may cure disease but can we afford them?

      CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs

    • Wednesday, 14 December, 2022
      UK business & economy
      UK watchdog probes sharp rise in cost of Strep A antibiotics

      CMA acknowledges ‘real concerns’ over pricing of drugs but is yet to launch formal investigation

    • Monday, 12 December, 2022
      Biotech
      Amgen to buy Horizon Therapeutics for $28.3bn

      California-based biotech wins three-way race to secure new drugs pipeline

    • Sunday, 11 December, 2022
      Health
      Amgen close to deal to buy Horizon Therapeutics for $20bn

      Drugmakers seek to replenish pharmaceuticals pipelines amid broader slowdown in transactions

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In